Neuroblastoma: The impact of biology and cooperation leading to personalized treatments

References

• Olshan A. Epidemiology. In: Cheung N-KV, Cohn SL, eds. Neuroblastoma. Berlin: Springer, 2005:1–5.
   Google Scholar
• Woods W. Screening for Neuroblastoma. In: Cheung N-KV, Cohn SL, eds. Neuroblastoma. Berlin: Springer, 2005:7–18.
   Google Scholar
• Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106–2120.
   PubMed Web of Science ®Google Scholar
• Franks LM, Bollen A, Seeger RC, Stram DO, Matthay KK. Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer 1997;79:2028–2035.
   PubMed Web of Science ®Google Scholar
• Gaspar N, Hartmann O, Munzer C, Bergeron C, Millot F, Cousin-Lafay L, et al. Neuroblastoma in adolescents. Cancer 2003;98:349–355.
   Google Scholar
• Gurney JG, Ross JA, Wall DA, Bleyer WA, Severson RK, Robison LL. Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol 1997;19:428–432.
   PubMed Web of Science ®Google Scholar
• O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009;373:1891–1904.
   PubMed Web of Science ®Google Scholar
• Hoffman JI. Incidence of congenital heart disease: I. Postnatal incidence. Pediatr Cardiol 1995;16:103–113.
   PubMed Web of Science ®Google Scholar
• Hauser WA. The prevalence and incidence of convulsive disorders in children. Epilepsia 1994;35:S1–S6.
   PubMed Web of Science ®Google Scholar
• Gurney JG, Davis S, Severson RK, Fang JY, Ross JA, Robison LL. Trends in cancer incidence among children in the U.S. Cancer 1996;78:532–541.
   PubMed Web of Science ®Google Scholar
• Brodeur GM, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, eds. Principles and practice of pediatric oncology. Philadelphia: Lippincott Williams & Wilkins, 2006:933–970.
   Google Scholar
• Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010;362:2202–2211.
   PubMed Web of Science ®Google Scholar
• Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27:289–297.
   PubMed Web of Science ®Google Scholar
• Gross RE, Farber S, Martin LW. Neuroblastoma sympatheticum; a study and report of 217 cases. Pediatrics 1959;23:1179–1191.
   PubMed Web of Science ®Google Scholar
• Brodeur GM. Molecular basis for heterogeneity in human neuroblastomas. Eur J Cancer 1995;31A:505–510.
   PubMed Web of Science ®Google Scholar
• Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264–2279.
   PubMed Web of Science ®Google Scholar
• Lau LM, Irwin MS. Molecular pathogenesis of neuroblastoma. In: Chang G, Newton and Vogelbaum, ed. Principles and Practice of Neuro-Oncology. New York: Demos Medical Publishing, 2011:225–238.
   Google Scholar
• Moroz V, Machin D, Faldum A, Hero B, Iehara T, Mosseri V, et al. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer 2011;47:561–571.
   PubMed Web of Science ®Google Scholar
• Goodman MT, Gurney JG, Smith MA, Olshan AF. Sympathetic nervous system tumors. In: Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR, eds. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975–1995. National Cancer Institute, SEER Program. NIH Pub. No. 99–4649. Bethesda, MD, 1999. Available at http://seer.cancer.gov/publications/childhood. Accessed on 16 May 2012.
   Google Scholar
• Lau L, Tai D, Weitzman S, Grant R, Baruchel S, Malkin D. Factors influencing survival in children with recurrent neuroblastoma. J Pediatr Hematol Oncol 2004;26:227–232.
   PubMed Web of Science ®Google Scholar
• London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol 2011;29:3286–3292.
   PubMed Web of Science ®Google Scholar
• Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer 2011;56:578–583.
   PubMed Web of Science ®Google Scholar
• Wright JH. Neurocytoma or neuroblastoma, a kind of tumor not generally recognized. J Exp Med 1910;12:556–561.
   PubMedGoogle Scholar
• Jiang M, Stanke J, Lahti JM. The connections between neural crest development and neuroblastoma. Curr Top Dev Biol 2011;94:77–127.
   PubMed Web of Science ®Google Scholar
• Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203–216.
   PubMed Web of Science ®Google Scholar
• Le Douarin NM, Kalcheim C. The Migration of Neural Crest Cells. The Neural Crest. 2nd ed. Cambridge: Cambridge University Press, 1999:23–58.
   Google Scholar
• Sauka-Spengler T, Bronner-Fraser M. A gene regulatory network orchestrates neural crest formation. Nat Rev Mol Cell Biol 2008;9:557–568.
   PubMed Web of Science ®Google Scholar
• Westermark UK, Wilhelm M, Frenzel A, Henriksson MA. The MYCN oncogene and differentiation in neuroblastoma. Semin Cancer Biol 2011;21:256–266.
   PubMed Web of Science ®Google Scholar
• Hossain MS, Ozaki T, Wang H, Nakagawa A, Takenobu H, Ohira M, et al. N-MYC promotes cell proliferation through a direct transactivation of neuronal leucine-rich repeat protein-1 (NLRR1) gene in neuroblastoma. Oncogene 2008;27:6075–6082.
   Google Scholar
• Huber K, Karch N, Ernsberger U, Goridis C, Unsicker K. The role of Phox2B in chromaffin cell development. Dev Biol 2005;279:501–508.
   Google Scholar
• Hervonen A. Development of catecholamine – storing cells in human fetal paraganglia and adrenal medulla. A histochemical and electron microscopical study. Acta Physiol Scand Suppl 1971;368:1–94.
   Google Scholar
• Tuchman M, Ramnaraine ML, Woods WG, Krivit W. Three years of experience with random urinary homovanillic and vanillylmandelic acid levels in the diagnosis of neuroblastoma. Pediatrics 1987;79:203–205.
   PubMedGoogle Scholar
• Turkel SB, Itabashi HH. The natural history of neuroblastic cells in the fetal adrenal gland. Am J Pathol 1974;76:225–244.
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Lister J, Bouton JM, Buyukpamukcu M. Congenital neuroblastoma, neuroblastoma in situ, and the normal fetal development of the adrenal. J Pediatr Surg 1981;16:636–644.
   Google Scholar
• Beckwith JB, Perrin EV. In situ neuroblastomas: a contribution to the natural history of neural crest tumors. Am J Pathol 1963;43:1089–1104.
   PubMed Web of Science ®Google Scholar
• Shimada H. In situ neuroblastoma: an important concept related to the natural history of neural crest tumors. Pediatr Dev Pathol 2005;8:305–306.
   Google Scholar
• Nakagawara A. Neural crest development and neuroblastoma: the genetic and biological link. Prog Brain Res 2004;146:233–242.
   PubMed Web of Science ®Google Scholar
• Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999;86:349–363.
   PubMed Web of Science ®Google Scholar
• Nakagawara A. Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities. Hum Cell 1998;11:115–124.
   Google Scholar
• Brodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varela CR, et al. Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res 2009;15:3244–3250.
   PubMed Web of Science ®Google Scholar
• Shojaei-Brosseau T, Chompret A, Abel A, de Vathaire F, Raquin MA, Brugieres L, et al. Genetic epidemiology of neuroblastoma: a study of 426 cases at the Institut Gustave-Roussy in France. Pediatr Blood Cancer 2004;42:99–105.
   PubMed Web of Science ®Google Scholar
• Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930–935.
   PubMed Web of Science ®Google Scholar
• Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455:967–970.
   PubMed Web of Science ®Google Scholar
• Hurley SP, Clary DO, Copie V, Lefcort F. Anaplastic lymphoma kinase is dynamically expressed on subsets of motor neurons and in the peripheral nervous system. J Comp Neurol 2006;495:202–212.
   PubMedGoogle Scholar
• Degoutin J, Brunet-de Carvalho N, Cifuentes-Diaz C, Vigny M. ALK (Anaplastic Lymphoma Kinase) expression in DRG neurons and its involvement in neuron-Schwann cells interaction. Eur J Neurosci 2009;29:275–286.
   Google Scholar
• de Pontual L, Kettaneh D, Gordon CT, Oufadem M, Boddaert N, Lees M, et al. Germline gain-of-function mutations of ALK disrupt central nervous system development. Hum Mutat 2011;32:272–276.
   Google Scholar
• Azarova AM, Gautam G, George RE. Emerging importance of ALK in neuroblastoma. Semin Cancer Biol 2011;21:267–275.
   PubMed Web of Science ®Google Scholar
• Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455:971–974.
   PubMed Web of Science ®Google Scholar
• George RE, Sanda T, Hanna M, Frohling S, Luther W 2nd, Zhang J, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008;455:975–978.
   PubMed Web of Science ®Google Scholar
• Schulte JH, Bachmann HS, Brockmeyer B, Depreter K, Oberthur A, Ackermann S, et al. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin Cancer Res 2011;17:5082–5092.
   PubMed Web of Science ®Google Scholar
• Martinsson T, Eriksson T, Abrahamsson J, Caren H, Hansson M, Kogner P, et al. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy. Cancer Res 2011;71:98–105.
   PubMed Web of Science ®Google Scholar
• De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 2010;16:4353–4362.
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561–566.
   PubMed Web of Science ®Google Scholar
• Mosse YP, Laudenslager M, Khazi D, Carlisle AJ, Winter CL, Rappaport E, et al. Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet 2004;75:727–730.
   PubMed Web of Science ®Google Scholar
• Trochet D, Bourdeaut F, Janoueix-Lerosey I, Deville A, de Pontual L, Schleiermacher G, et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet 2004;74:761–764.
   PubMed Web of Science ®Google Scholar
• Huber K. The sympathoadrenal cell lineage: specification, diversification, and new perspectives. Dev Biol 2006;298:335–343.
   PubMed Web of Science ®Google Scholar
• Raabe EH, Laudenslager M, Winter C, Wasserman N, Cole K, LaQuaglia M, et al. Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. Oncogene 2008;27:469–476.
   PubMed Web of Science ®Google Scholar
• Trochet D, Hong SJ, Lim JK, Brunet JF, Munnich A, Kim KS, et al. Molecular consequences of PHOX2B missense, frameshift and alanine expansion mutations leading to autonomic dysfunction. Hum Mol Genet 2005;14:3697–3708.
   PubMed Web of Science ®Google Scholar
• Reiff T, Tsarovina K, Majdazari A, Schmidt M, del Pino I, Rohrer H. Neuroblastoma phox2b variants stimulate proliferation and dedifferentiation of immature sympathetic neurons. J Neurosci 2010;30:905–915.
   PubMed Web of Science ®Google Scholar
• McConville C, Reid S, Baskcomb L, Douglas J, Rahman N. PHOX2B analysis in non-syndromic neuroblastoma cases shows novel mutations and genotype-phenotype associations. Am J Med Genet A 2006;140:1297–1301.
   PubMedGoogle Scholar
• Serra A, Haberle B, Konig IR, Kappler R, Suttorp M, Schackert HK, et al. Rare occurrence of PHOX2b mutations in sporadic neuroblastomas. J Pediatr Hematol Oncol 2008;30:728–732.
   Google Scholar
• Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res 2001;61:8–13.
   Google Scholar
• Carr J, Bell E, Pearson AD, Kees UR, Beris H, Lunec J, et al. Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. Cancer Res 2006;66:2138–2145.
   Web of Science ®Google Scholar
• Carr-Wilkinson J, O’Toole K, Wood KM, Challen CC, Baker AG, Board JR, et al. High Frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma. Clin Cancer Res 2010;16:1108–1118.
   PubMed Web of Science ®Google Scholar
• Deyell RJ, Attiyeh EF. Advances in the understanding of constitutional and somatic genomic alterations in neuroblastoma. Cancer Genet 2011;204:113–121.
   Google Scholar
• Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993;328:847–854.
   PubMed Web of Science ®Google Scholar
• Mosse YP, Diskin SJ, Wasserman N, Rinaldi K, Attiyeh EF, Cole K, et al. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chromosomes Cancer 2007;46:936–949.
   PubMed Web of Science ®Google Scholar
• Light JE, Koyama H, Minturn JE, Ho R, Simpson AM, Iyer R, et al. Clinical significance of NTRK family gene expression in neuroblastomas. Pediatr Blood Cancer 2011; Oct 11. doi: 10.1002/pbc.23343. [Epub ahead of print].
   Google Scholar
• Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 1994;14:759–767.
   PubMed Web of Science ®Google Scholar
• Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Klijanienko J, Couturier J, Pierron G, et al. Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol 2010;28:3122–3130.
   PubMed Web of Science ®Google Scholar
• Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 2009;100:1471–1482.
   PubMed Web of Science ®Google Scholar
• Moreau LA, McGrady P, London WB, Shimada H, Cohn SL, Maris JM, et al. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children’s Oncology Group study. Clin Cancer Res 2006;12:5693–5697.
   Google Scholar
• Thompson EB. The many roles of c-Myc in apoptosis. Annu Rev Physiol 1998;60:575–600.
   PubMed Web of Science ®Google Scholar
• Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002;2:764–776.
   PubMed Web of Science ®Google Scholar
• Neckers LM, Rosolen A, Whitesell L. Antisense inhibition of gene expression: a tool for studying the role of NMYC in the growth and differentiation of neuroectoderm-derived cells. J Immunother (1991) 1992;12:162–166.
   Google Scholar
• Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997;16:2985–2995.
   PubMed Web of Science ®Google Scholar
• Caron H, van Sluis P, van Hoeve M, de Kraker J, Bras J, Slater R, et al. Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification. Nat Genet 1993;4:187–190.
   PubMed Web of Science ®Google Scholar
• Guo C, White PS, Hogarty MD, Brodeur GM, Gerbing R, Stram DO, et al. Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas. Med Pediatr Oncol 2000;35:544–546.
   Google Scholar
• White PS, Thompson PM, Gotoh T, Okawa ER, Igarashi J, Kok M, et al. Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene 2005;24:2684–2694.
   Google Scholar
• Fong CT, Dracopoli NC, White PS, Merrill PT, Griffith RC, Housman DE, et al. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci USA 1989;86:3753–3757.
   PubMed Web of Science ®Google Scholar
• Maris JM, Weiss MJ, Guo C, Gerbing RB, Stram DO, White PS, et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children’s Cancer Group study. J Clin Oncol 2000;18:1888–1899.
   PubMed Web of Science ®Google Scholar
• Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005;353:2243–2253.
   PubMed Web of Science ®Google Scholar
• Bader SA, Fasching C, Brodeur GM, Stanbridge EJ. Dissociation of suppression of tumorigenicity and differentiation in vitro effected by transfer of single human chromosomes into human neuroblastoma cells. Cell Growth Differ 1991;2:245–255.
   PubMedGoogle Scholar
• Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D, et al. CHD5 is a tumor suppressor at human 1p36. Cell 2007;128:459–475.
   PubMed Web of Science ®Google Scholar
• Munirajan AK, Ando K, Mukai A, Takahashi M, Suenaga Y, Ohira M, et al. KIF1Bbeta functions as a haploinsufficient tumor suppressor gene mapped to chromosome 1p36.2 by inducing apoptotic cell death. J Biol Chem 2008;283:24426–24434.
   PubMed Web of Science ®Google Scholar
• Caron H, Peter M, van Sluis P, Speleman F, de Kraker J, Laureys G, et al. Evidence for two tumour suppressor loci on chromosomal bands 1p35–36 involved in neuroblastoma: one probably imprinted, another associated with N-myc amplification. Hum Mol Genet 1995;4:535–539.
   PubMed Web of Science ®Google Scholar
• Okawa ER, Gotoh T, Manne J, Igarashi J, Fujita T, Silverman KA, et al. Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene 2008;27:803–810.
   Google Scholar
• Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, Kolla V, et al. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst 2008;100:940–949.
   PubMedGoogle Scholar
• Garcia I, Mayol G, Rodriguez E, Sunol M, Gershon TR, Rios J, et al. Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Mol Cancer 2010;9:277.
   PubMed Web of Science ®Google Scholar
• Schlisio S, Kenchappa RS, Vredeveld LC, George RE, Stewart R, Greulich H, et al. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev 2008;22:884–893.
   PubMed Web of Science ®Google Scholar
• Guo C, White PS, Weiss MJ, Hogarty MD, Thompson PM, Stram DO, et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 1999;18:4948–4957.
   PubMed Web of Science ®Google Scholar
• Bown N, Cotterill S, Lastowska M, O’Neill S, Pearson AD, Plantaz D, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999;340:1954–1961.
   PubMed Web of Science ®Google Scholar
• Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000;19:617–623.
   PubMed Web of Science ®Google Scholar
• Godfried MB, Veenstra M, v Sluis P, Boon K, v Asperen R, Hermus MC, et al. The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2. Oncogene 2002;21:2097–2101.
   Google Scholar
• Bowman LC, Castleberry RP, Cantor A, Joshi V, Cohn SL, Smith EI, et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst 1997;89:373–380.
   Google Scholar
• Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991;9:581–591.
   PubMed Web of Science ®Google Scholar
• Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984;311:231–235.
   PubMed Web of Science ®Google Scholar
• Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 2010;363:1313–1323.
   PubMed Web of Science ®Google Scholar
• Iyer R, Evans AE, Qi X, Ho R, Minturn JE, Zhao H, et al. Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma. Clin Cancer Res 2010;16:1478–1485.
   PubMed Web of Science ®Google Scholar
• Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, et al. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemother Pharmacol 2011;68:1057–1065.
   PubMed Web of Science ®Google Scholar
• Nguyen le B, Diskin SJ, Capasso M, Wang K, Diamond MA, Glessner J, et al. Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci. PLoS Genet 2011;7:e1002026.
   PubMed Web of Science ®Google Scholar
• Wang K, Diskin SJ, Zhang H, Attiyeh EF, Winter C, Hou C, et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature 2011;469:216–220.
   PubMed Web of Science ®Google Scholar
• Diskin SJ, Hou C, Glessner JT, Attiyeh EF, Laudenslager M, Bosse K, et al. Copy number variation at 1q21.1 associated with neuroblastoma. Nature 2009;459:987–991.
   PubMed Web of Science ®Google Scholar
• Capasso M, Devoto M, Hou C, Asgharzadeh S, Glessner JT, Attiyeh EF, et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet 2009;41:718–723.
   PubMed Web of Science ®Google Scholar
• De Preter K, Vermeulen J, Brors B, Delattre O, Eggert A, Fischer M, et al. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin Cancer Res 2010;16:1532–1541.
   PubMed Web of Science ®Google Scholar
• Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H, et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 2006;98:1193–1203.
   PubMed Web of Science ®Google Scholar
• Vermeulen J, De Preter K, Laureys G, Speleman F, Vandesompele J. 59-gene prognostic signature sub-stratifies high-risk neuroblastoma patients. Lancet Oncol 2009;10:1030.
   Google Scholar
• Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y, et al. Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 2010;28:3506–3515.
   PubMed Web of Science ®Google Scholar
• Abe M, Watanabe N, McDonell N, Takato T, Ohira M, Nakagawara A, et al. Identification of genes targeted by CpG island methylator phenotype in neuroblastomas, and their possible integrative involvement in poor prognosis. Oncology 2008;74:50–60.
   PubMed Web of Science ®Google Scholar
• Yang Q, Kiernan CM, Tian Y, Salwen HR, Chlenski A, Brumback BA, et al. Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin Cancer Res 2007;13:3191–3197.
   PubMed Web of Science ®Google Scholar
• Decock A, Ongenaert M, Vandesompele J, Speleman F. Neuroblastoma epigenetics: From candidate gene approaches to genome-wide screenings. Epigenetics 2011;6:962–970.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281–297.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li Y, Lai M. The microRNA network and tumor metastasis. Oncogene 2010;29:937–948.
   PubMed Web of Science ®Google Scholar
• Chen Y, Stallings RL. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 2007;67:976–983.
   PubMed Web of Science ®Google Scholar
• Guo J, Dong Q, Fang Z, Chen X, Lu H, Wang K, et al. Identification of miRNAs that are associated with tumor metastasis in neuroblastoma. Cancer Biol Ther 2010;9:446–452.
   PubMedGoogle Scholar
• Bray I, Bryan K, Prenter S, Buckley PG, Foley NH, Murphy DM, et al. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One 2009;4:e7850.
   Google Scholar
• Wei JS, Johansson P, Chen QR, Song YK, Durinck S, Wen X, et al. microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies. Clin Cancer Res 2009;15:5560–5568.
   PubMed Web of Science ®Google Scholar
• De Preter K, Mestdagh P, Vermeulen J, Zeka F, Naranjo A, Bray I, et al. miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. Clin Cancer Res 2011;17:7684–7692.
   PubMed Web of Science ®Google Scholar
• Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998;279:349–352.
   PubMed Web of Science ®Google Scholar
• Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1995;1:249–255.
   PubMed Web of Science ®Google Scholar
• Poremba C, Scheel C, Hero B, Christiansen H, Schaefer KL, Nakayama J, et al. Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: a molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues. J Clin Oncol 2000;18:2582–2592.
   PubMed Web of Science ®Google Scholar
• Ohali A, Avigad S, Ash S, Goshen Y, Luria D, Feinmesser M, et al. Telomere length is a prognostic factor in neuroblastoma. Cancer 2006;107:1391–1399.
   PubMed Web of Science ®Google Scholar
• Hiyama E, Hiyama K, Ohtsu K, Yamaoka H, Ichikawa T, Shay JW, et al. Telomerase activity in neuroblastoma: is it a prognostic indicator of clinical behaviour? Eur J Cancer 1997;33:1932–1936.
   PubMed Web of Science ®Google Scholar
• Joshi VV, Silverman JF. Pathology of neuroblastic tumors. Semin Diagn Pathol 1994;11:107–117.
   PubMed Web of Science ®Google Scholar
• Variend S, Burchill SA. Neuroblastoma. In: Cullinane CJ, Burchill SA, Squire JA, O’Leary JJ, Lewis IJ, eds. Molecular biology and pathology of paediatric cancer. Oxford: Oxford University Press, 2003:155–170.
   Google Scholar
• Schwab M, Joshi VV. Peripheral neuroblastic tumours. In: Kleihaus P, Cavenee WK, eds. Pathology and genetics of tumours of the nervous system. Lyon: IARC Scientific Publications, 1997:117–125.
   Google Scholar
• De Bernardi B, Gambini C, Haupt R, Granata C, Rizzo A, Conte M, et al. Retrospective study of childhood ganglioneuroma. J Clin Oncol 2008;26:1710–1716.
   Google Scholar
• Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999;86:364–372.
   PubMed Web of Science ®Google Scholar
• Shimada H, Chatten J, Newton WA Jr, Sachs N, Hamoudi AB, Chiba T, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984;73:405–416.
   PubMed Web of Science ®Google Scholar
• Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, Goto S, et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children’s Cancer Group. Cancer 2001;92:2451–2461.
   PubMed Web of Science ®Google Scholar
• Peuchmaur M, d’Amore ES, Joshi VV, Hata J, Roald B, Dehner LP, et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 2003;98:2274–2281.
   PubMed Web of Science ®Google Scholar
• Okamatsu C, London WB, Naranjo A, Hogarty MD, Gastier-Foster JM, Look AT, et al. Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG. Pediatr Blood Cancer 2009;53:563–569.
   PubMedGoogle Scholar
• Kushner BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med 2004;45:1172–1188.
   PubMed Web of Science ®Google Scholar
• Coldman AJ, Fryer CJ, Elwood JM, Sonley MJ. Neuroblastoma: influence of age at diagnosis, stage, tumor site, and sex on prognosis. Cancer 1980;46:1896–1901.
   PubMedGoogle Scholar
• Papaioannou G, McHugh K. Neuroblastoma in childhood: review and radiological findings. Cancer Imaging 2005;5:116–127.
   PubMedGoogle Scholar
• Woods WG, Tuchman M, Robison LL, Bernstein M, Leclerc JM, Brisson LC, et al. A population-based study of the usefulness of screening for neuroblastoma. Lancet 1996;348:1682–1687.
   PubMed Web of Science ®Google Scholar
• Schilling FH, Spix C, Berthold F, Erttmann R, Fehse N, Hero B, et al. Neuroblastoma screening at one year of age. N Engl J Med 2002;346:1047–1053.
   PubMed Web of Science ®Google Scholar
• Hiyama E, Iehara T, Sugimoto T, Fukuzawa M, Hayashi Y, Sasaki F, et al. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study. Lancet 2008;371:1173–1180.
   PubMed Web of Science ®Google Scholar
• Ho PT, Estroff JA, Kozakewich H, Shamberger RC, Lillehei CW, Grier HE, et al. Prenatal detection of neuroblastoma: a ten-year experience from the Dana-Farber Cancer Institute and Children’s Hospital. Pediatrics 1993;92:358–364.
   PubMed Web of Science ®Google Scholar
• Jennings RW, LaQuaglia MP, Leong K, Hendren WH, Adzick NS. Fetal neuroblastoma: prenatal diagnosis and natural history. J Pediatr Surg 1993;28:1168–1174.
   PubMed Web of Science ®Google Scholar
• Holgersen LO, Subramanian S, Kirpekar M, Mootabar H, Marcus JR. Spontaneous resolution of antenatally diagnosed adrenal masses. J Pediatr Surg 1996;31:153–155.
   Google Scholar
• Carlsen NL, Schroeder H, Bro PV, Erichsen G, Hamborg-Pedersen B, Jensen KB, et al. Neuroblastomas treated at the four major child oncologic clinics in Denmark 1943–1980: an evaluation of 180 cases. Med Pediatr Oncol 1985;13:180–186.
   PubMedGoogle Scholar
• Berthold F, Simon T. Clinical Presentation. In: Cheung N-KV, Cohn SL, eds. Neuroblastoma. Berlin: Springer, 2005: 63–83.
   Google Scholar
• Hiorns MP, Owens CM. Radiology of neuroblastoma in children. Eur Radiol 2001;11:2071–2081.
   Google Scholar
• Hutchison R. On suprarenal sarcoma in children with metastases to the skull. Q J Med 1907;1:33–38.
   Google Scholar
• Belgaumi AF, Kauffman WM, Jenkins JJ, Cordoba J, Bowman LC, Santana VM, et al. Blindness in children with neuroblastoma. Cancer 1997;80:1997–2004.
   Google Scholar
• Lau JJ, Trobe JD, Ruiz RE, Cho RW, Wechsler DS, Shah GV, et al. Metastatic neuroblastoma presenting with binocular blindness from intracranial compression of the optic nerves. J Neuroophthalmol 2004;24:119–124.
   Google Scholar
• D’Angio GJ, Evans AE, Koop CE. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1971;1:1046–1049.
   PubMed Web of Science ®Google Scholar
• Evans AE, Chatten J, D’Angio GJ, Gerson JM, Robinson J, Schnaufer L. A review of 17 IV-S neuroblastoma patients at the children’s hospital of philadelphia. Cancer 1980;45:833–839.
   PubMed Web of Science ®Google Scholar
• Pepper W. A study of congenital sarcoma of the liver and suprarenal with report of a case. Am J Med Sci 1901;121:287–299.
   Google Scholar
• Hsu LL, Evans AE, D’Angio GJ. Hepatomegaly in neuroblastoma stage 4s: criteria for treatment of the vulnerable neonate. Med Pediatr Oncol 1996;27:521–528.
   PubMedGoogle Scholar
• van Noesel MM, Hahlen K, Hakvoort-Cammel FG, Egeler RM. Neuroblastoma 4S: a heterogeneous disease with variable risk factors and treatment strategies. Cancer 1997;80:834–843.
   PubMed Web of Science ®Google Scholar
• Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children’s Cancer Group study. J Clin Oncol 2000;18:477–486.
   PubMed Web of Science ®Google Scholar
• Taggart DR, London WB, Schmidt ML, Dubois SG, Monclair TF, Nakagawara A, et al. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol 2011;29:4358–4364.
   PubMed Web of Science ®Google Scholar
• Levitt GA, Platt KA, De Byrne R, Sebire N, Owens CM. 4S neuroblastoma: the long-term outcome. Pediatr Blood Cancer 2004;43:120–125.
   Google Scholar
• French AE, Irwin MS, Navarro OM, Greenberg M, Nathan PC. Long-term hepatic outcomes in survivors of stage 4S and 4 neuroblastoma in infancy. Pediatr Blood Cancer 2012; 58:283–288.
   Google Scholar
• Woodruff G, Buncic JR, Morin JD. Horner’s syndrome in children. J Pediatr Ophthalmol Strabismus 1988;25:40–44.
   Google Scholar
• George ND, Gonzalez G, Hoyt CS. Does Horner’s syndrome in infancy require investigation? Br J Ophthalmol 1998;82:51–54.
   Web of Science ®Google Scholar
• Mahoney NR, Liu GT, Menacker SJ, Wilson MC, Hogarty MD, Maris JM. Pediatric horner syndrome: etiologies and roles of imaging and urine studies to detect neuroblastoma and other responsible mass lesions. Am J Ophthalmol 2006;142:651–659.
   Web of Science ®Google Scholar
• Plantaz D, Rubie H, Michon J, Mechinaud F, Coze C, Chastagner P, et al. The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease. A prospective study of 42 patients--results of the NBL 90 Study of the French Society of Pediatric Oncology. Cancer 1996;78:311–319.
   PubMedGoogle Scholar
• Katzenstein HM, Kent PM, London WB, Cohn SL. Treatment and outcome of 83 children with intraspinal neuroblastoma: the Pediatric Oncology Group experience. J Clin Oncol 2001;19:1047–1055.
   PubMed Web of Science ®Google Scholar
• Morris JA, Shcochat SJ, Smith EI, Look AT, Brodeur GM, Cantor AB, et al. Biological variables in thoracic neuroblastoma: a Pediatric Oncology Group study. J Pediatr Surg 1995;30:296–302; discussion 302-293.
   Google Scholar
• Mitchell WG, Davalos-Gonzalez Y, Brumm VL, Aller SK, Burger E, Turkel SB, et al. Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics 2002;109:86–98.
   PubMedGoogle Scholar
• Rudnick E, Khakoo Y, Antunes NL, Seeger RC, Brodeur GM, Shimada H, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children’s Cancer Group Study. Med Pediatr Oncol 2001;36:612–622.
   PubMedGoogle Scholar
• Swart JF, de Kraker J, van der Lely N. Metaiodobenzylguanidine total-body scintigraphy required for revealing occult neuroblastoma in opsoclonus-myoclonus syndrome. Eur J Pediatr 2002;161:255–258.
   PubMedGoogle Scholar
• Hayward K, Jeremy RJ, Jenkins S, Barkovich AJ, Gultekin SH, Kramer J, et al. Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies. J Pediatr 2001;139:552–559.
   PubMed Web of Science ®Google Scholar
• Bourdeaut F, de Carli E, Timsit S, Coze C, Chastagner P, Sarnacki S, et al. VIP hypersecretion as primary or secondary syndrome in neuroblastoma: A retrospective study by the Societe Francaise des Cancers de l’Enfant (SFCE). Pediatr Blood Cancer 2009;52:585–590.
   Google Scholar
• Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466–1477.
   PubMed Web of Science ®Google Scholar
• Voorhess ML, Gardner LI. Studies of catecholamine excretion by children with neural tumors. J Clin Endocrinol Metab 1962;22:126–133.
   Google Scholar
• Gitlow SE, Bertani LM, Rausen A, Gribetz D, Dziedzic SW. Diagnosis of neuroblastoma by qualitative and quantitative determination of catecholamine metabolites in urine. Cancer 1970;25:1377–1383.
   PubMed Web of Science ®Google Scholar
• Laug WE, Siegel SE, Shaw KN, Landing B, Baptista J, Gutenstein M. Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma. Pediatrics 1978;62:77–83.
   PubMed Web of Science ®Google Scholar
• Monsaingeon M, Perel Y, Simonnet G, Corcuff JB. Comparative values of catecholamines and metabolites for the diagnosis of neuroblastoma. Eur J Pediatr 2003;162:397–402.
   Google Scholar
• Kushnir MM, Urry FM, Frank EL, Roberts WL, Shushan B. Analysis of catecholamines in urine by positive-ion electrospray tandem mass spectrometry. Clin Chem 2002;48:323–331.
   PubMed Web of Science ®Google Scholar
• Peaston RT, Weinkove C. Measurement of catecholamines and their metabolites. Ann Clin Biochem 2004;41:17–38.
   PubMed Web of Science ®Google Scholar
• Tuchman M, Morris CL, Ramnaraine ML, Bowers LD, Krivit W. Value of random urinary homovanillic acid and vanillylmandelic acid levels in the diagnosis and management of patients with neuroblastoma: comparison with 24-hour urine collections. Pediatrics 1985;75:324–328.
   PubMed Web of Science ®Google Scholar
• O’Meara A, Tormey W, FitzGerald RJ, Fitzgibbon M, Kenny D. Interpretation of random urinary catecholamines and their metabolites in neuroblastoma. Acta Paediatr 1994;83:88–92.
   Google Scholar
• Fitzgibbon M, FitzGerald RJ, Tormey WP, O’Meara A, Kenny D. Reference values for urinary HMMA, HVA, noradrenaline, adrenaline, and dopamine excretion in children using random urine samples and HPLC with electrochemical detection. Ann Clin Biochem 1992;29 (Pt 4):400–404.
   Google Scholar
• Pussard E, Neveux M, Guigueno N. Reference intervals for urinary catecholamines and metabolites from birth to adulthood. Clin Biochem 2009;42:536–539.
   PubMed Web of Science ®Google Scholar
• Tsunoda M. Recent advances in methods for the analysis of catecholamines and their metabolites. Anal Bioanal Chem 2006;386:506–514.
   PubMed Web of Science ®Google Scholar
• Erdelyi DJ, Elliott M, Phillips B. Urine catecholamines in paediatrics. Arch Dis Child Educ Pract Ed 2011;96:107–111.
   Google Scholar
• Nakagawara A, Ikeda K, Higashi K, Sasazuki T. Inverse correlation between N-myc amplification and catecholamine metabolism in children with advanced neuroblastoma. Surgery 1990;107:43–49.
   PubMed Web of Science ®Google Scholar
• Izbicki T, Bozek J, Perek D, Wozniak W. Urinary dopamine/noradrenaline and dopamine/vanillylmandelic acid ratios as a reflection of different biology of adrenergic clones in children’s neuroblastic tumors. J Pediatr Surg 1991;26:1230–1234.
   PubMed Web of Science ®Google Scholar
• Barontini M, Gutierrez MI, Levin G, Mur N, Diez B. N-myc oncogene and urinary catecholamines in children with neuroblastoma. Med Pediatr Oncol 1993;21:499–504.
   PubMedGoogle Scholar
• Strenger V, Kerbl R, Dornbusch HJ, Ladenstein R, Ambros PF, Ambros IM, et al. Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients. Pediatr Blood Cancer 2007;48:504–509.
   PubMed Web of Science ®Google Scholar
• Hann HW, Levy HM, Evans AE. Serum ferritin as a guide to therapy in neuroblastoma. Cancer Res 1980;40:1411–1413.
   PubMed Web of Science ®Google Scholar
• Giler S, Moroz C. The significance of ferritin in malignant diseases. Biomedicine 1978;28:203–206.
   PubMedGoogle Scholar
• White GP, Worwood M, Parry DH, Jacobs A. Ferritin synthesis in normal and leukaemic leukocytes. Nature 1974;250:584–586.
   PubMed Web of Science ®Google Scholar
• Hann HW, Evans AE, Siegel SE, Wong KY, Sather H, Dalton A, et al. Prognostic importance of serum ferritin in patients with Stages III and IV neuroblastoma: the Childrens Cancer Study Group experience. Cancer Res 1985;45:2843–2848.
   PubMed Web of Science ®Google Scholar
• Imashuku S, Yamanaka H, Morioka Y, Todo S. Serum ferritin in stage IV neuroblastoma. Am J Pediatr Hematol Oncol 1988;10:39–41.
   Google Scholar
• Kirino T, Brightman MW, Oertel WH, Schmechel DE, Marangos PJ. Neuron-specific enolase as an index of neuronal regeneration and reinnervation. J Neurosci 1983;3:915–923.
   PubMed Web of Science ®Google Scholar
• Guzel A, Er U, Tatli M, Aluclu U, Ozkan U, Duzenli Y, et al. Serum neuron-specific enolase as a predictor of short-term outcome and its correlation with Glasgow Coma Scale in traumatic brain injury. Neurosurg Rev 2008;31:439–444; discussion 444-435.
   PubMed Web of Science ®Google Scholar
• Sandler SJ, Figaji AA, Adelson PD. Clinical applications of biomarkers in pediatric traumatic brain injury. Child Nerv Syst 2010;26:205–213.
   PubMed Web of Science ®Google Scholar
• Seeger RC, Zeltzer PM, Rayner SA. Onco-neural antigen: a new neural differentiation antigen expressed by neuroblastoma, oat cell carcinoma, Wilms’ tumor, and sarcoma cells. J Immunol 1979;122:1548–1555.
   Google Scholar
• Zeltzer PM, Marangos PJ, Parma AM, Sather H, Dalton A, Hammond D, et al. Raised neuron-specific enolase in serum of children with metastatic neuroblastoma. A report from the Children’s Cancer Study Group. Lancet 1983;2:361–363.
   PubMed Web of Science ®Google Scholar
• Zeltzer PM, Marangos PJ, Evans AE, Schneider SL. Serum neuron-specific enolase in children with neuroblastoma. Relationship to stage and disease course. Cancer 1986;57:1230–1234.
   PubMed Web of Science ®Google Scholar
• Quinn JJ, Altman AJ, Frantz CN. Serum lactic dehydrogenase, an indicator of tumor activity in neuroblastoma. J Pediatr 1980;97:89–91.
   PubMed Web of Science ®Google Scholar
• Shuster JJ, McWilliams NB, Castleberry R, Nitschke R, Smith EI, Altshuler G, et al. Serum lactate dehydrogenase in childhood neuroblastoma. A Pediatric Oncology Group recursive partitioning study. Am J Clin Oncol 1992;15:295–303.
   Google Scholar
• Joshi VV, Tsongalis GJ. Correlation between morphologic and nonmorphologic prognostic markers of neuroblastoma. Ann NY Acad Sci 1997;824:71–83.
   PubMed Web of Science ®Google Scholar
• Joshi VV, Cantor AB, Brodeur GM, Look AT, Shuster JJ, Altshuler G, et al. Correlation between morphologic and other prognostic markers of neuroblastoma. A study of histologic grade, DNA index, N-myc gene copy number, and lactic dehydrogenase in patients in the Pediatric Oncology Group. Cancer 1993;71:3173–3181.
   PubMed Web of Science ®Google Scholar
• Rubie H, Michon J, Plantaz D, Peyroulet MC, Coze C, Frappaz D, et al. Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Societe Francaise d’Oncologie Pediatrique (SFOP). Br J Cancer 1998;77:2310–2317.
   PubMedGoogle Scholar
• Lau L. Neuroblastoma: a single institution’s experience with 128 children and an evaluation of clinical and biological prognostic factors. Pediatr Hematol Oncol 2002;19:79–89.
   Web of Science ®Google Scholar
• Mora J, Gerald WL, Cheung NK. Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma. Cancer Lett 2003;197:119–124.
   Google Scholar
• Kaste SC, McCarville MB. Imaging pediatric abdominal tumors. Semin Roentgenol 2008;43:50–59.
   Google Scholar
• Chu CM, Rasalkar DD, Hu YJ, Cheng FW, Li CK, Chu WC. Clinical presentations and imaging findings of neuroblastoma beyond abdominal mass and a review of imaging algorithm. Br J Radiol 2011;84:81–91.
   Google Scholar
• Ng YY, Kingston JE. The role of radiology in the staging of neuroblastoma. Clin Radiol 1993;47:226–235.
   Google Scholar
• Brisse H, Edeline V, Michon J, Couanet D, Zucker J, Neuenschwander S. Strategie actuelle d’imagerie des neuroblastomes. [Current strategy for the imaging of neuroblastoma]. JRadiol 2001;82:447–454.
   Google Scholar
• Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011;261:243–257.
   PubMed Web of Science ®Google Scholar
• Meyer JS, Siegel MJ, Farooqui SO, Jaramillo D, Fletcher BD, Hoffer FA. Which MRI sequence of the spine best reveals bone-marrow metastases of neuroblastoma? Pediatr Radiol 2005;35:778–785.
   PubMed Web of Science ®Google Scholar
• Tanabe M, Ohnuma N, Iwai J, Yoshida H, Takahashi H, Maie M, et al. Bone marrow metastasis of neuroblastoma analyzed by MRI and its influence on prognosis. Med Pediatr Oncol 1995;24:292–299.
   Google Scholar
• Dubois SG, London WB, Zhang Y, Matthay KK, Monclair T, Ambros PF, et al. Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer 2008;51:589–592.
   PubMed Web of Science ®Google Scholar
• Howman-Giles R, Shaw PJ, Uren RF, Chung DK. Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med 2007;37:286–302.
   Google Scholar
• Leung A, Shapiro B, Hattner R, Kim E, de Kraker J, Ghazzar N, et al. Specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 1997;38:1352–1357.
   Google Scholar
• Kushner BH, Kramer K, Modak S, Cheung NK. Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol 2009;27:1041–1046.
   Google Scholar
• Gelfand MJ. Meta-iodobenzylguanidine in children. Semin Nucl Med 1993;23:231–242.
   PubMedGoogle Scholar
• Carrasquillo JA, Chen CC. Molecular imaging of neuroendocrine tumors. Semin Oncol 2010;37:662–679.
   PubMed Web of Science ®Google Scholar
• Garaventa A. Does a “false-negative” MIBG scan predict a better outcome in neuroblastoma patients? Med Pediatr Oncol 2001;37:418.
   Google Scholar
• Chan GC, Leung YL, Shing MM, Luk CW, Ling SC, Lee AC. Does a “false negative” MIBG scan predict a better outcome in neuroblastoma patients? Med Pediatr Oncol 2001;37:155.
   Google Scholar
• Biasotti S, Garaventa A, Villavecchia GP, Cabria M, Nantron M, De Bernardi B. False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Med Pediatr Oncol 2000;35:153–155.
   Google Scholar
• van Santen HM, de Kraker J, van Eck BL, de Vijlder JJ, Vulsma T. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma. Cancer 2002;94:2081–2089.
   Google Scholar
• Picco P, Garaventa A, Claudiani F, Garibaldi L, Borrone C. Primary hypothyroidism and 131I-MIBG therapy in neuroblastoma. Lancet 1993;342:57.
   Google Scholar
• Picco P, Garaventa A, Claudiani F, Gattorno M, De Bernardi B, Borrone C. Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma. Cancer 1995;76:1662–1664.
   Google Scholar
• Kaste SC. PET-CT in children: where is it appropriate? Pediatr Radiol 2011;41(Suppl 2):509–513.
   Google Scholar
• Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villablanca JG, et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol 2009;27:5343–5349.
   PubMed Web of Science ®Google Scholar
• Franzius C. FDG-PET/CT in pediatric solid tumors. Q J Nucl Med Mol Imaging 2010;54:401–410.
   Google Scholar
• Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med 2009;50:1237–1243.
   PubMed Web of Science ®Google Scholar
• Ady N, Zucker JM, Asselain B, Edeline V, Bonnin F, Michon J, et al. A new 123I-MIBG whole body scan scoring method – application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 1995;31A:256–261.
   PubMed Web of Science ®Google Scholar
• Yanik GA, Parisi MT, Naranjo A, Matthay KK, London WB, McGrady PW, et al. MIBG scoring as a prognostic indicator in patients with stage IV neuroblastoma: A COG study. J Clin Oncol 2010;28(Suppl):15s (Abstr 9516).
   Google Scholar
• Suc A, Lumbroso J, Rubie H, Hattchouel JM, Boneu A, Rodary C, et al. Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system. Cancer 1996;77:805–811.
   Web of Science ®Google Scholar
• Katzenstein HM, Cohn SL, Shore RM, Bardo DM, Haut PR, Olszewski M, et al. Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol 2004;22:3909–3915.
   Google Scholar
• Matthay KK, Edeline V, Lumbroso J, Tanguy ML, Asselain B, Zucker JM, et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003;21:2486–2491.
   Google Scholar
• Messina JA, Cheng SC, Franc BL, Charron M, Shulkin B, To B, et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 2006;47:865–874.
   PubMed Web of Science ®Google Scholar
• Matthay KK, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V, et al. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer 2010;102:1319–1326.
   PubMed Web of Science ®Google Scholar
• Naranjo A, Parisi MT, Shulkin BL, London WB, Matthay KK, Kreissman SG, et al. Comparison of (1)(2)(3)I-metaiodobenzylguanidine (MIBG) and (1)(3)(1)I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2011;56:1041–1045.
   PubMed Web of Science ®Google Scholar
• Castleberry RP, Pritchard J, Ambros P, Berthold F, Brodeur GM, Castel V, et al. The International Neuroblastoma Risk Groups (INRG): a preliminary report. Eur J Cancer 1997;33:2113–2116.
   PubMed Web of Science ®Google Scholar
• Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009;27:298–303.
   PubMed Web of Science ®Google Scholar
• Bagatell R, Beck-Popovic M, London WB, Zhang Y, Pearson AD, Matthay KK, et al. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J Clin Oncol 2009;27:365–370.
   PubMed Web of Science ®Google Scholar
• Cecchetto G, Mosseri V, De Bernardi B, Helardot P, Monclair T, Costa E, et al. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol 2005;23:8483–8489.
   Google Scholar
• Simon T, Hero B, Benz-Bohm G, von Schweinitz D, Berthold F. Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trial. Pediatr Blood Cancer 2008;50:965–969.
   PubMedGoogle Scholar
• Breslow N, McCann B. Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 1971;31:2098–2103.
   PubMed Web of Science ®Google Scholar
• Hartmann O, Valteau-Couanet D, Vassal G, Lapierre V, Brugieres L, Delgado R, et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transpl 1999;23:789–795.
   PubMed Web of Science ®Google Scholar
• Simon T, Spitz R, Faldum A, Hero B, Berthold F. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol 2004;26:791–796.
   Google Scholar
• Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O’Leary M, et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children’s Cancer Group Study. J Clin Oncol 2005;23:6474–6480.
   PubMed Web of Science ®Google Scholar
• George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 2005;23:6466–6473.
   PubMed Web of Science ®Google Scholar
• London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J Clin Oncol 2005;23:6459–6465.
   PubMed Web of Science ®Google Scholar
• Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121–1124.
   PubMed Web of Science ®Google Scholar
• Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111–1116.
   PubMed Web of Science ®Google Scholar
• Rubie H, Hartmann O, Michon J, Frappaz D, Coze C, Chastagner P, et al. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Societe Francaise d’Oncologie Pediatrique. J Clin Oncol 1997;15:1171–1182.
   Google Scholar
• Valteau-Couanet D, Benhamou E, Vassal G, Stambouli F, Lapierre V, Couanet D, et al. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma. Bone Marrow Transpl 2000;25:937–942.
   Google Scholar
• Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study. J Clin Oncol 2009;27:1007–1013.
   PubMed Web of Science ®Google Scholar
• Park JR, Villablanca JG, London WB, Gerbing RB, Haas-Kogan D, Adkins ES, et al. Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2009;52:44–50.
   PubMed Web of Science ®Google Scholar
• Canete A, Gerrard M, Rubie H, Castel V, Di Cataldo A, Munzer C, et al. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol 2009;27:1014–1019.
   PubMed Web of Science ®Google Scholar
• Wittenborg M. Roentgen therapy in neuroblastoma: a review of 73 cases. Radiology 1950;54:679–685.
   Google Scholar
• Matthay KK, Sather HN, Seeger RC, Haase GM, Hammond GD. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 1989;7:236–244.
   Google Scholar
• Kushner BH, Cheung NK, LaQuaglia MP, Ambros PF, Ambros IM, Bonilla MA, et al. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol 1996;14:373–381.
   Google Scholar
• Evans AE, Silber JH, Shpilsky A, D’Angio GJ. Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J Clin Oncol 1996;14:2504–2510.
   Google Scholar
• De Bernardi B, Gerrard M, Boni L, Rubie H, Canete A, Di Cataldo A, et al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol 2009;27:1034–1040.
   PubMed Web of Science ®Google Scholar
• Gupta A, Kumar A, Walters S, Chait P, Irwin MS, Gerstle JT. Analysis of needle versus open biopsy for the diagnosis of advanced stage pediatric neuroblastoma. Pediatr Blood Cancer 2006;47:875–879.
   Google Scholar
• Shah NB, Platt SL. ALARA: is there a cause for alarm? Reducing radiation risks from computed tomography scanning in children. Curr Opin Pediatr 2008;20:243–247.
   Web of Science ®Google Scholar
• Chong AL, Grant RM, Ahmed BA, Thomas KE, Connolly BL, Greenberg M. Imaging in pediatric patients: time to think again about surveillance. Pediatr Blood Cancer 2010;55:407–413.
   PubMed Web of Science ®Google Scholar
• Umehara S, Nakagawa A, Matthay KK, Lukens JN, Seeger RC, Stram DO, et al. Histopathology defines prognostic subsets of ganglioneuroblastoma, nodular. Cancer 2000;89:1150–1161.
   Google Scholar
• Angelini P, London WB, Cohn SL, Pearson AD, Matthay KK, Monclair T, et al. Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: A report from the INRG project. Eur J Cancer 2012;48:1185–1191.
   PubMed Web of Science ®Google Scholar
• Modak S, Cheung NK. Neuroblastoma: Therapeutic strategies for a clinical enigma. Cancer Treat Rev 2010;36:307–317.
   PubMed Web of Science ®Google Scholar
• Garaventa A, De Bernardi B, Pianca C, Donfrancesco A, Cordero di Montezemolo L, Di Tullio MT, et al. Localized but unresectable neuroblastoma: treatment and outcome of 145 cases. Italian Cooperative Group for Neuroblastoma. J Clin Oncol 1993;11:1770–1779.
   Google Scholar
• Matthay KK, Perez C, Seeger RC, Brodeur GM, Shimada H, Atkinson JB, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children’s Cancer Group study. J Clin Oncol 1998;16:1256–1264.
   PubMed Web of Science ®Google Scholar
• Castleberry RP, Kun LE, Shuster JJ, Altshuler G, Smith IE, Nitschke R, et al. Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. J Clin Oncol 1991;9:789–795.
   PubMedGoogle Scholar
• West DC, Shamberger RC, Macklis RM, Kozakewich HP, Wayne AS, Kreissman SG, et al. Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents. J Clin Oncol 1993;11:84–90.
   Google Scholar
• Castel V, Badal MD, Bezanilla JL, Llombart A, Ruiz-Jimenez JI, Sanchez de Toledo J, et al. Treatment of stage III neuroblastoma with emphasis on intensive induction chemotherapy: a report from the Neuroblastoma Group of the Spanish Society of Pediatric Oncology. Med Pediatr Oncol 1995;24:29–35.
   PubMedGoogle Scholar
• de Bernardi B, Rogers D, Carli M, Madon E, de Laurentis T, Bagnulo S, et al. Localized neuroblastoma. Surgical and pathologic staging. Cancer 1987;60:1066–1072.
   PubMedGoogle Scholar
• Rubie H, Coze C, Plantaz D, Munzer C, Defachelles AS, Bergeron C, et al. Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy. Br J Cancer 2003;89:1605–1609.
   Google Scholar
• Modak S, Kushner BH, LaQuaglia MP, Kramer K, Cheung NK. Management and outcome of stage 3 neuroblastoma. Eur J Cancer 2009;45:90–98.
   Google Scholar
• Rubie H, De Bernardi B, Gerrard M, Canete A, Ladenstein R, Couturier J, et al. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol 2011;29:449–455.
   PubMedGoogle Scholar
• Park JR, London WB, Maris JM, Shimada H, Zhang Y, Matthay KK, Monclair T, Ambros PF, Cohn SL, Pearson A. Prognostic markers for stage 3 neuroblastoma (NB): A report from the International Neuroblastoma Risk Group (INRG) project. J Clin Oncol 2008;26 :(May 20 suppl; abstr 10009).
   Google Scholar
• Ohnuma N, Takahashi H, Kaneko M, Uchino J, Takeda T, Iwafuchi M, et al. Treatment combined with bone marrow transplantation for advanced neuroblastoma: an analysis of patients who were pretreated intensively with the protocol of the Study Group of Japan. Med Pediatr Oncol 1995;24:181–187.
   PubMedGoogle Scholar
• Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med 1999;341:1165–1173.
   PubMed Web of Science ®Google Scholar
• Philip T, Ladenstein R, Lasset C, Hartmann O, Zucker JM, Pinkerton R, et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer 1997;33:2130–2135.
   PubMedGoogle Scholar
• Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D, et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 2004;22:3549–3557.
   PubMed Web of Science ®Google Scholar
• Zage PE, Kletzel M, Murray K, Marcus R, Castleberry R, Zhang Y, et al. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2008;51:747–753.
   PubMedGoogle Scholar
• Ladenstein R, Potschger U, Hartman O, Pearson AD, Klingebiel T, Castel V, et al. 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transpl 2008;41(Suppl 2):S118–S127.
   Google Scholar
• Kushner BH, LaQuaglia MP, Bonilla MA, Lindsley K, Rosenfield N, Yeh S, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 1994;12:2607–2613.
   PubMed Web of Science ®Google Scholar
• Kushner BH, Heller G, Kramer K, Cheung NK. Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma. Cancer 2000;89:2122–2130.
   Google Scholar
• Valteau-Couanet D, Faucher C, Auperin A, Michon J, Milpied N, Boiron JM, et al. Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial. Bone Marrow Transpl 2005;36:547–552.
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Valteau-Couanet D, Brock P, Yaniv I, Castel V, Laureys G, et al. Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J Clin Oncol 2010;28:3516–3524.
   PubMed Web of Science ®Google Scholar
• London WB, Frantz CN, Campbell LA, Seeger RC, Brumback BA, Cohn SL, et al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children’s Oncology Group study. J Clin Oncol 2010;28:3808–3815.
   PubMed Web of Science ®Google Scholar
• Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 2008;9:247–256.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Simon T, Hero B, Schicha H, Berthold F. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer 2008;44:1552–1558.
   PubMed Web of Science ®Google Scholar
• Stutterheim J, Zappeij-Kannegieter L, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA. The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma. Eur J Cancer 2011;47:1193–1202.
   Google Scholar
• Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Kleijn I, Dee R, Hooft L, et al. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. J Clin Oncol 2008;26:5443–5449.
   Google Scholar
• Cheung IY, Feng Y, Gerald W, Cheung NK. Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma. Clin Cancer Res 2008;14:7020–7027.
   Google Scholar
• Viprey VF, Corrias MV, Kagedal B, Oltra S, Swerts K, Vicha A, et al. Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: quality assurance on behalf of SIOPEN-R-NET. Eur J Cancer 2007;43:341–350.
   Google Scholar
• Cheung IY, Lo Piccolo MS, Kushner BH, Kramer K, Cheung NK. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma. J Clin Oncol 2003;21:1087–1093.
   PubMed Web of Science ®Google Scholar
• Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005;6:649–658.
   PubMed Web of Science ®Google Scholar
• Pritchard J, Cotterill SJ, Germond SM, Imeson J, de Kraker J, Jones DR. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer 2005;44:348–357.
   PubMed Web of Science ®Google Scholar
• Philip T, Ladenstein R, Zucker JM, Pinkerton R, Bouffet E, Louis D, et al. Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study. Br J Cancer 1993;67:119–127.
   PubMed Web of Science ®Google Scholar
• George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger RC, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol 2006;24:2891–2896.
   PubMed Web of Science ®Google Scholar
• Sung KW, Lee SH, Yoo KH, Jung HL, Cho EJ, Koo HH, et al. Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma. Bone Marrow Transpl 2007;40:37–45.
   Google Scholar
• Sidell N. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J Natl Cancer Inst 1982;68:589–596.
   PubMed Web of Science ®Google Scholar
• Villablanca JG, Khan AA, Avramis VI, Seeger RC, Matthay KK, Ramsay NK, et al. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 1995;13:894–901.
   PubMed Web of Science ®Google Scholar
• Schulz G, Cheresh DA, Varki NM, Yu A, Staffileno LK, Reisfeld RA. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 1984;44:5914–5920.
   PubMed Web of Science ®Google Scholar
• Cheung NK, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987;5:1430–1440.
   PubMed Web of Science ®Google Scholar
• Yu AL, Uttenreuther-Fischer MM, Huang CS, Tsui CC, Gillies SD, Reisfeld RA, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 1998;16:2169–2180.
   PubMed Web of Science ®Google Scholar
• Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324–1334.
   PubMed Web of Science ®Google Scholar
• Cheung NK, Kushner BH, Yeh SJ, Larson SM. 3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: a phase II study. Prog Clin Biol Res 1994;385:319–328.
   PubMedGoogle Scholar
• Cheung NK, Kushner BH, LaQuaglia M, Kramer K, Gollamudi S, Heller G, et al. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol 2001;36:227–230.
   PubMedGoogle Scholar
• Kushner BH, Kramer K, Modak S, Cheung NK. Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study. J Clin Oncol 2011;29:1168–1174.
   PubMed Web of Science ®Google Scholar
• Cheung NK, Sowers R, Vickers AJ, Cheung IY, Kushner BH, Gorlick R. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol 2006;24:2885–2890.
   PubMed Web of Science ®Google Scholar
• Garaventa A, Guerra P, Arrighini A, Bertolazzi L, Bestagno M, De Bernardi B, et al. Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine. Cancer 1991;67:922–928.
   Google Scholar
• Lumbroso J, Hartmann O, Schlumberger M. Therapeutic use of [131I]metaiodobenzylguanidine in neuroblastoma: a phase II study in 26 patients. “Societe Francaise d’Oncologie Pediatrique” and Nuclear Medicine Co-investigators. J Nucl Biol Med 1991;35:220–223.
   Google Scholar
• Klingebiel T, Feine U, Treuner J, Reuland P, Handgretinger R, Niethammer D. Treatment of neuroblastoma with [131I]metaiodobenzylguanidine: long-term results in 25 patients. J Nucl Biol Med 1991;35:216–219.
   Google Scholar
• Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A, et al. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998;16:229–236.
   Google Scholar
• Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007;25:1054–1060.
   PubMed Web of Science ®Google Scholar
• Johnson K, McGlynn B, Saggio J, Baniewicz D, Zhuang H, Maris JM, et al. Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma. Pediatr Blood Cancer 2011;57:1124–1129.
   PubMed Web of Science ®Google Scholar
• Yanik GA, Levine JE, Matthay KK, Sisson JC, Shulkin BL, Shapiro B, et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 2002;20:2142–2149.
   PubMedGoogle Scholar
• Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 2006;24:500–506.
   PubMed Web of Science ®Google Scholar
• de Kraker J, Hoefnagel KA, Verschuur AC, van Eck B, van Santen HM, Caron HN. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer 2008;44:551–556.
   PubMed Web of Science ®Google Scholar
• Kushner BH, Kramer K, Modak S, Cheung NK. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 2006;24:5271–5276.
   PubMed Web of Science ®Google Scholar
• Bagatell R, London WB, Wagner LM, Voss SD, Stewart CF, Maris JM, et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children’s Oncology Group study. J Clin Oncol 2011;29:208–213.
   PubMed Web of Science ®Google Scholar
• Kumar S, Mokhtari RB, Sheikh R, Wu B, Zhang L, Xu P, et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res 2011;17:5656–5667.
   PubMed Web of Science ®Google Scholar
• Pasquier E, Kieran MW, Sterba J, Shaked Y, Baruchel S, Oberlin O, et al. Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. Transl Oncol 2011;4:203–211.
   PubMed Web of Science ®Google Scholar
• Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166–178.
   PubMed Web of Science ®Google Scholar
• Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol 2012 Mar 5. [epub ahead of print].
   Google Scholar
• Stevens M. Oberlin O, Carli M. European Soft TIssue Sarcoma Group (EpSSG) Rhabdmomyosarcoma 2005 protocol. Available from http://epssg.cineca.org/clinical_trials.htm. Accessed on 16 May 2012.
   Google Scholar
• Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009;27:2278–2287.
   PubMed Web of Science ®Google Scholar
• Fulda S. The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma. Curr Cancer Drug Targets 2009;9:729–737.
   Google Scholar
• Bagatell R IM, Cohn SL. Predicting outcomes, tailoring therapy, and targeting tumor-initiating cells in children with neuroblstoma. ASCO 2011 Educational Book. Chicago 2011. p. 1–7. Available at http://www.asco.org/ascov2/Education+&+Training/Educational+Book?&vmview=edbk_detail_view&confID=102&abstractID=1055. Accessed on 16 May 2012.
   Google Scholar
• Lau LM, Irwin MS. Neuroblastoma. In: eLS. Chichester: John Wiley & Sons Ltd; 2011. Published online: March 2011. DOI: 10.1002/9780470015902.a0006054.pub2. Available from: http://www.els.net/WileyCDA/ElsArticle/refId-a0006054.html. Accessed on 16 May 2012.
   Google Scholar
• Smith KM, Datti A, Fujitani M, Grinshtein N, Zhang L, Morozova O, et al. Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens. EMBO Mol Med 2010;2:371–384.
   Google Scholar
• Grinshtein N, Datti A, Fujitani M, Uehling D, Prakesch M, Isaac M, et al. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res 2011;71:1385–1395.
   PubMed Web of Science ®Google Scholar
• Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci USA 2011;108:3336–3341.
   PubMed Web of Science ®Google Scholar
• Castelo-Branco P, Zhang C, Lipman T, Fujitani M, Hansford L, Clarke I, et al. Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition. Clin Cancer Res 2011;17:111–121.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–247.
   PubMed Web of Science ®Google Scholar